CRISPR Therapeutics AG
CRSPHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats. The $4.78B market capitalization puts CRSP squarely in mid-cap range for its industry. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Market Cap
$4.78B
Beta
1.76
P/E (TTM)
—
P/E (Fwd)
-13.90
EPS (TTM)
$-4.74
EPS (Fwd)
$-3.55
ROE
-26.1%
ROA
-14.2%
Cash
$2.36B
Total Debt
$783.7M
Free CF
-$215.8M
52W Change
-24.9%
Annual Financials
Cash vs Debt
Where CRSP stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, CRSP finished 1.06% above its 150-day moving average ($52.83) and 0.30% above its 200-day moving average ($53.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRSP overbought or oversold?
At the October 12, 2026 close, CRSP's RSI(14) was 37.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $2.36B in cash comfortably exceeding the $783.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$215.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -26.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $436K (2022) to $0 (2025), a 100% decline worth watching.
With a beta above 1.5, CRSP tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, CRSP has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CRSP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.